Management Team



Chief Executive Officer

Daniel Silva Manzano, PhD

Chief Executive Officer

Daniel is a biochemist, entrepreneur, and world-renowned expert in de novo protein design. Daniel completed his undergraduate degree and Ph.D. at UNAM (Mexico), has authored multiple peer-reviewed publications in high-impact journals and is an inventor on several patents. Among his accomplishments, he was the main architect behind NL-201, the first de novo protein to reach clinical trials.

Alfredo Quijano Rubio, PhD

Chief Scientific Officer

Alfredo graduated in Bioengineering from the UW IPD under David Baker's mentorship. His research focuses on de novo protein design of conditionally-active protein systems that can address challenges in immunotherapy and diagnostics. He has authored multiple scientific publications in high-impact peer-reviewed journals and has published numerous patents describing his inventions.



Chief Scientific Officer


Principal Scientist

Starting Immediately

Senior Scientist

Starting Immediately

Research Associate

Starting Immediately

Sr. Director, Business Development & Commercialization

Starting Summer 2022

Finance & Operations Associate

Starting June 2022



Chief Operating Officer


David Shoultz, PhD, MBA

Chief Operating Officer

David obtained his PhD in epidemiology from the University of Washington, and his MBA from the Albers School of Business & Economics at Seattle University. His background spans multiple therapeutic areas with particular expertise in infectious diseases, global health, and non-dilutive financing. He is an experienced executive leader and product developer with expertise in diagnostics, drugs, vaccines, and medical devices.

Contact Us

Fluke Hall – University of Washington

4000 Mason Road

Seattle, WA 98105

Thanks for submitting!


Send us your CV or resume.